Page 78 - Read Online

Cordero et al. Bioresorbable scaffolds in acute coronary syndrome

Table 2: Procedure and coronary lesions characteristics
Characteristics No stent BMS DES BVS P
Radial approach 93.0% 96.4% 98.1% 100.0% 0.01
No. of vessels with lesions, mean ± SD 0.8 ± 1.1 1.6 ± 0.8 1.7 ± 0.8 2.1 ± 0.8 < 0.01
No. of stents/patient, mean ± SD 0.0 ± 0.0 1.4 ± 0.6 1.6 ± 0.9 2.8 ± 1.5 < 0.01
Complete revascularization 49.0% 71.4% 76.3% 85.2% < 0.01
Left main disease 7.1% 0.6% 6.1% 0.0% < 0.01
Coronary lesions < 0.01
1 vessel disease 13.1% 59.9% 47.4% 24.1%
2 vessel disease 13.1% 22.2% 29.8% 42.6%
3 vessel disease 5.7% 16.8% 16.5% 33.3%
LM + 1 vessel disease 1.6% 0.0% 0.6% 0.0%
LM + 2 vessel disease 0.8% 0.0% 2.3% 0.0%
LM + 3 vessel disease 6.6% 0.6% 3.2% 0.0%
BMS: bare metal stent; DES: drug-eluting stents; BVS: bioresorvable vascular scaffold; LM: left main

Table 3: Medical treatments recommended at discharge according to the stent received within hospital revascularization
Characteristics No stent BMS DES BVS P
Aspirin 76.9% 96.4% 96.6% 98.1% 0.01
Clopidogrel 25.6% 64.3% 43.5% 29.6% < 0.01
Ticagrelor 5.8% 14.9% 28.3% 31.5% < 0.01
Prasugrel 0.0% 17.3% 25.6% 38.9% < 0.01
Any new antiplatelet 5.8% 32.1% 53.9% 70.4% < 0.01
DAPT 18.6% 92.9% 94.5% 98.1% < 0.01
Oral anticoagulants 14.1% 10.1% 5.3% 0.0% < 0.01
ARB/ACEI 71.2% 79.2% 82.0% 79.6% 0.03
Beta blockers 64.7% 83.3% 88.4% 90.7% < 0.01
Diuretics 37.2% 26.8% 19.5% 11.1% < 0.01
Statins 69.2% 95.2% 95.1% 96.3% < 0.01
High dose statin 32.1% 70.8% 73.6% 83.3% < 0.01
Moderate dose statin 29.5% 16.7% 16.9% 13.0% < 0.01
Low dose statin 7.7% 6.5% 1.7% 0.0% < 0.01
Nitrates 19.9% 6.5% 4.7% 1.9% < 0.01
Fibrates 1.9% 3.0% 1.9% 1.9% 0.87
Ezetimibe 1.9% 0.6% 4.0% 1.9% 0.10
Optimal medical treatment 33.3% 63.7% 70.4% 66.7% < 0.01
BMS: bare metal stent; DES: drug-eluting stents; BVS: bioresorvable vascular scaffold; DAPT: double antiplatelet treatment; ARB:
angiotensin receptor blocker; ACEI: angiotensin-converter enzyme inhibitors
the prevalence of diabetes or dyslipidaemia according The highest in-hospital mortality rate was observed in
to the stent type received. BMS-treated patients had patients who were not (or could not be) stented (8.8%),
the highest prevalence of comorbidities, reflected by followed by those treated with BMS (7.2%) and DES
the highest mean Charlson index. (3.3%). As shown in Table 3, BVS-treated patients
received the highest rate of dual antiplatelet treatment
The details of the revascularisation outcomes are and 70% received a new antiplatelet drug (prasugrel
presented in Table 2. The radial artery approach was or ticagrelor). Generally, patients treated with DES or
utilised in most cases and in all BVS-treated subjects. BVS received more intensive medical treatments.
The mean number of coronary lesions was 1.6 (± 0.9)
which was significantly higher in BVS-treated subjects; Post-discharge follow-up was achieved in 95.0% of the
the mean number of stents per subject was 1.3 (± 1.0) cohort, with median time of 13 months (interquartile
and BVS-treated cases also had the highest rate. As a range 9.0 to 22.0). All-cause mortality was 7.8%, and
consequence, the rate of complete revascularisation cardiovascular mortality was 6.1%. Additionally, 26.4%
was the highest in patients treated with BVS. No BVS subjects experienced at least one MACE. Kaplan-Meier
implantations were attempted in the left main coronary curves are presented in Figure 1. All-cause mortality
artery. varied according to stent type: no stent (13.5%), BMS
(10.1%), DES (5.7%), and BVS (5.6%); the differences
In-hospital mortality was 4.8% (46 patients out of 951) were significant (log-rank test, P < 0.01). Cardiovascular
and no patient treated with BVS died prior to discharge. mortality declined in the same order: no stent (10.3%),
Vessel Plus ¦ Volume 1 ¦ June 27, 2017 71